Four, resmetirom confers significant advantages to patient cohorts who do not meet the indication of GLP-1 therapies, including individuals who have already attained weight reduction and populations not afflicted with diabetes
This is why research on GLP-1 function in metabolism has expanded rapidly in recent years, influencing fields ranging from obesity science to diabetes care
Phase 2 trial data (NEJM, 2023) showed mean body weight reductions at higher doses over 48 weeks, but Phase 3 confirmation and long-term safety data are still pending
Lost, damaged & returns If your order arrives damaged or tracking shows an issue, contact us within 7 days with your order number, photos, and any tracking details
Always discuss your complete medical history, current medications, and any concerns with your healthcare provider before starting treatment
We evaluated stCAT through a simulation using existing PROMIS anxiety (PROMIS-A) and depression (PROMIS-D) CAT scores